PK2
Alternative Names: HPMA copolymer doxorubicin PK2; Liver-targeted doxorubicin-HPMA conjugateLatest Information Update: 24 Oct 2021
At a glance
- Originator Nonindustrial source
- Class Anthracyclines; Cytostatic antibiotics
- Mechanism of Action Asialoglycoprotein receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 28 Sep 1999 Phase-I clinical trials for Liver cancer in United Kingdom (IV-infusion)